CYTK logo

Cytokinetics Incorporated (CYTK)

$51.65

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CYTK

Market cap

$7.20B

EPS

-6.05

P/E ratio

--

Price to sales

129.24

Dividend yield

--

Beta

0.456958

Price on CYTK

Previous close

$53.17

Today's open

$52.68

Day's range

$51.37 - $52.98

52 week range

$51.37 - $88.31

Profile about CYTK

CEO

Robert I. Blum

Employees

673

Headquarters

South San Francisco, CA

Exchange

Nasdaq Global Select

Shares outstanding

139303351

Issue type

Common Stock

CYTK industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CYTK

Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing

Cytokinetics NASDAQ: CYTK executives said the company is seeing momentum in the launch of heart drug MYQORZO and is preparing to seek U.S. approval for its use in a second form of hypertrophic cardiomyopathy.

news source

MarketBeat • Nov 17, 2026

news preview

Cytokinetics' MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market

Cytokinetics NASDAQ: CYTK executives said the launch of its heart drug MYQORZO is gaining prescribers and market share as the company prepares regulatory submissions that could expand use of aficamten, the drug's active ingredient.

news source

MarketBeat • Nov 16, 2026

news preview

Cytokinetics, Incorporated (CYTK) Presents at UBS Global Biopharma Conference 2026 Transcript

Cytokinetics, Incorporated (CYTK) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM

MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker Metoprolol

news source

GlobeNewsWire • Nov 16, 2026

news preview

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 13, 2026 it granted stock options to purchase an aggregate of 64,110 shares of common stock and 42,496 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in October and November 2026 as a material inducement to their employment.

news source

GlobeNewsWire • Nov 16, 2026

news preview

Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for Aficamten

news source

GlobeNewsWire • Nov 9, 2026

news preview

Cytokinetics Q3 Earnings Call Highlights

Cytokinetics NASDAQ: CYTK reported $44.5 million in third-quarter net revenue from heart drug MYQORZO, up 76% from the prior quarter, as the company prepares regulatory submissions that could expand the treatment's use.

news source

MarketBeat • Nov 5, 2026

news preview

Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript

Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update

MYQORZO ® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027 ~$1.6 Billion in Cash, Cash Equivalents and Investments as of September 30, 2026 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2026.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.37 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $1.54 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Cytokinetics Incorporated

Open an M1 investment account to buy and sell Cytokinetics Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CYTK on M1